Anesthetic

Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL® for the Management of Postsurgical Pain after Open Inguinal Hernia Surgery

Retrieved on: 
Thursday, March 26, 2020
Health, Articles, Medication, Pharmaceutical industry, Pharmaceutical industry in China, Local anesthetic, Food and Drug Administration, Anesthetic, Specialty

"The FDA acceptance of the NDA for XARACOLL brings us a step closer to providing a new and innovative non-opioid solution to surgeons and patients looking to manage postsurgical pain," said Rich Fante, CEO of Innocoll.

Key Points: 
  • "The FDA acceptance of the NDA for XARACOLL brings us a step closer to providing a new and innovative non-opioid solution to surgeons and patients looking to manage postsurgical pain," said Rich Fante, CEO of Innocoll.
  • XARACOLL is a late-stage bioresorbable collagen-matrix surgical implant being developed by Innocoll for the management of postsurgical pain relief through the delivery of bupivacaine, a local anesthetic, at the surgical site.
  • Innocoll Holdings Limited is a global specialty pharmaceutical company headquartered in Athlone, Ireland.
  • Innocoll Holdings Limited and its subsidiary, Innocoll Pharmaceuticals Limited, are focused on the development and commercialization of pharmaceutical technologies to meet some of today's most important healthcare challenges.

Insights Into the Anesthetics Industry, 2015-2030 - Market was Valued at $9.32 Billion in 2018 and is Expected to Decline to $9.13 Billion by 2022

Retrieved on: 
Wednesday, March 4, 2020
Anesthetic, GABAA receptor positive allosteric modulators, General anesthetics, Combination drugs, Local anesthetics, Ethers

The global anesthetics market was valued at about $9.32 billion in 2018 and is expected to decline to $9.13 billion at a CAGR of -0.5% through 2022.

Key Points: 
  • The global anesthetics market was valued at about $9.32 billion in 2018 and is expected to decline to $9.13 billion at a CAGR of -0.5% through 2022.
  • North America was the largest region in the anesthetics market in 2017, followed by Europe.
  • Stringent guidelines and regulations imposed by regulatory bodies are one of the important restraints for the anesthetics market.
  • Regulations such as these are expected to keep a check on the general anesthetic drugs market.

Sedana Medical Donates AnaConDa to Hospitals in Wuhan, China

Retrieved on: 
Thursday, February 27, 2020
Anesthesia, Fictional characters, Sedation, Inhalation sedation, Anesthetic, Anaconda, Elements of fiction

STOCKHOLM, Feb. 27, 2020 /PRNewswire/ --Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.

Key Points: 
  • STOCKHOLM, Feb. 27, 2020 /PRNewswire/ --Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.
  • Sedana Medical is a pioneer in making volatile anaesthetics available to critically ill mechanically ventilated patients via the medical device AnaConDa.
  • To begin with, we will donate 300 AnaConDa and related accessories to evaluate the effects of inhalation sedation with AnaConDa on severely ill Corona virus infected patients."
  • Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanicallyventilated patients.

Sedana Medical Donates AnaConDa to Hospitals in Wuhan, China

Retrieved on: 
Thursday, February 27, 2020
Anesthesia, Fictional characters, Sedation, Inhalation sedation, Anesthetic, Anaconda, Elements of fiction

STOCKHOLM, Feb. 27, 2020 /PRNewswire/ --Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.

Key Points: 
  • STOCKHOLM, Feb. 27, 2020 /PRNewswire/ --Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.
  • Sedana Medical is a pioneer in making volatile anaesthetics available to critically ill mechanically ventilated patients via the medical device AnaConDa.
  • To begin with, we will donate 300 AnaConDa and related accessories to evaluate the effects of inhalation sedation with AnaConDa on severely ill Corona virus infected patients."
  • Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanicallyventilated patients.

Anesthesia Drugs Market Insights, 2020-2025 - New Approvals of Anesthetic Drugs, Reduction in the Cost of Newly Invented Drugs

Retrieved on: 
Monday, February 17, 2020
Anesthesia, Anesthesiology, Anesthetic, Branches of biology

The key factors propelling the growth of this market are the increasing number of surgeries and new approvals of anesthetic drugs.

Key Points: 
  • The key factors propelling the growth of this market are the increasing number of surgeries and new approvals of anesthetic drugs.
  • This indicates the rising number of surgeries, which ultimately results into the rising demand for the anesthesia drugs and propels the growth of the anesthesia drugs market.
  • North America currently dominates the anesthesia drugs market and is expected to continue its stronghold for a few more years.
  • Companies, like Baxter, Abbott Laboratories, AstraZeneca, Roche Holding AG, and B. Braun Melsungen AG, hold substantial market shares in the anesthesia drugs market.

Lannett Announces FDA Approval Of NDA For Branded Anesthetic Product, Cocaine Hydrochloride Nasal Solution 4%

Retrieved on: 
Monday, January 13, 2020
Psychoactive drugs, Drugs, Medical specialties, Local anesthetics, RTT, Euphoriants, Sodium channel blockers, Cocaine, Ketamine, Anesthetic, Anesthesia, Local anesthesia

PHILADELPHIA, Jan. 13, 2020 /PRNewswire/ --Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway, for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL), the company's branded local anesthetic product.

Key Points: 
  • PHILADELPHIA, Jan. 13, 2020 /PRNewswire/ --Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway, for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL), the company's branded local anesthetic product.
  • "The FDA's approval of our Cocaine HCl product, the first NDA approval to include full clinical trials in the company's history, marks a major milestone in Lannett's 70+ years of operations," said Tim Crew, chief executive officer of Lannett.
  • "We believe the product has the potential to be an excellent option for the labeled indication.
  • NUMBRINO (cocaine hydrochloride) nasal solution is an ester local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.

Global Inhalation Anesthetics Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 3, 2020
Health, Pharmaceutical, General anesthetics, Branches of biology, Neurochemistry, Psychoactive drugs, NMDA receptor antagonists, GABAA receptor positive allosteric modulators, Vehicle modification, Industrial gases, Nitrous oxide, Anesthetic, Inhalational anesthetic, Inhalation

The "Inhalation Anesthetics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inhalation Anesthetics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The Inhalation Anesthetics market worldwide is projected to grow by US$335.4 Million, driven by a compounded growth of 3.7%.
  • Nitrous Oxide, one of the segments analyzed and sized in this study, displays the potential to grow at over 3.9%.
  • Poised to reach over US$1.1 Billion by the year 2025, Nitrous Oxide will bring in healthy gains adding significant momentum to global growth.

Global Anesthesia Gas Blenders Market 2019-2023 | Evolving Opportunities with Bio-Med Devices Inc. and EKU Elektronik GmbH | Technavio

Retrieved on: 
Tuesday, December 17, 2019
Health, Surgery, Other Health, Medical devices, Medical specialties, Fluid dynamics, Medicine, Anesthesia, Anesthesiology, Flow measurement, Inhalational anesthetic, Anesthetic

View the full release here: https://www.businesswire.com/news/home/20191217005310/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191217005310/en/
    Technavio has announced its latest market research report titled global anesthesia gas blenders market 2019-2023.
  • Anesthetic Gas Blenders Technology Outlook (Revenue, USD million, 2019-2023)
    The market will witness strong demand for dual-tube flowmeters over the forecast period.
  • Their growing popularity is encouraging many market vendors to introduce a wide range of dual-tube flow meter anesthesia gas blenders.
  • The North American region will retain its position as the largest market for anesthesia gas blenders over the forecast period.

Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain

Retrieved on: 
Monday, December 16, 2019
Perception, Medical specialties, Acute pain, RTT, Pain, Local anesthetics, Anesthetic, Bupivacaine, Analgesic

Itis the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and opioid use through 72 hours compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control.

Key Points: 
  • Itis the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and opioid use through 72 hours compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control.
  • The synergistic mechanism of action of HTX-011 was demonstrated in preclinical and clinical studies.
  • This maintenance of the physiologic pH level within the surgical site microenvironment was associated with potentiated and prolonged analgesic activity of bupivacaine.
  • "The inability of local anesthetics, including current extended release formulations, to demonstrate consistent postoperative pain relief beyond 24 hours creates challenges for both physicians and patients.

Global Anesthetics Market Report 2020 with Profiles of Key Players - Baxter, Abbott Laboratories, AstraZeneca, F. Hoffmann-La Roche AG, B. Braun Melsungen - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 11, 2019
Health, Pharmaceutical, Drugs, Psychoactive drugs, Neurochemistry, Anesthesia, Anesthetic, General anesthetics, NMDA receptor antagonists, Sodium channel blockers, Local anesthetic, Ketamine

The global anesthetics market was valued at about $9.32 billion in 2018 and is expected to decline to $9.13 billion at a CAGR of -0.5% through 2022.

Key Points: 
  • The global anesthetics market was valued at about $9.32 billion in 2018 and is expected to decline to $9.13 billion at a CAGR of -0.5% through 2022.
  • The anesthetics market consists of sales of drugs that cause a relaxing sensation to calm patients during surgery and remove the sensation of pain.
  • The anesthetics market is divided into general anesthetics, regional anesthetics and local anesthetics.
  • North America was the largest region in the anesthetics market in 2017, followed by Europe.